Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750857 | 0.85 | LMNA (0.72) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL24069550 | 0.84 | LMNA (0.60) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL6734172 | 0.84 | LMNA (0.63) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL9424254 | 0.83 | LMNA (0.74) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL10816709 | 0.82 | LMNA (0.72) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL6734167 | 0.81 | POLB (0.62) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL5837384 | 0.81 | LMNA (0.71) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL10996648 | 0.81 | LMNA (0.71) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL2378171 | 0.79 | LMNA (0.60) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| Carbofuran SCHEMBL21722098 | 0.78 | LMNA (1.00) | LMNAPOLBALDH1A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186170-A1 | Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient | EGIS GYOGYSZERGYAR (HU) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186170-A1 | Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient | CYP2F1, CYP3A4, CYP2S1 | LMNA 2499/4885POLB 1666/4885ALDH1A1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.